Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

Breast Cancer Highlights: ASCO 2015

2,539 views

Published on

Breast Cancer Highlights: ASCO 2015. Dr Banu Arun

Published in: Education
  • Be the first to comment

Breast Cancer Highlights: ASCO 2015

  1. 1. Breast Cancer Highlights- ASCO 2015 Banu Arun, M.D. Professor, Breast Medical Oncology Co-Director Clinical Cancer Genetics The University of Texas MD Anderson Cancer Center Bangkok, August, 2015
  2. 2. Objectives ● Her-2/neu positive ● ER positive ● Triple negative ● DCIS
  3. 3. Slide 2 Presented By Shanu Modi at 2015 ASCO Annual Meeting
  4. 4. Phase III, randomized study of trastuzumab emtansine ± pertuzumab vs trastuzumab + taxane for first-line treatment of HER2-positive MBC: Primary results from the MARIANNE study Presented By Paul Ellis at 2015 ASCO Annual Meeting
  5. 5. MARIANNE Study Design Presented By Shanu Modi at 2015 ASCO Annual Meeting
  6. 6. MARIANNE: Progression-Free Survival Presented By Shanu Modi at 2015 ASCO Annual Meeting
  7. 7. Overall Survival (First Interim Analysis) Presented By Paul Ellis at 2015 ASCO Annual Meeting
  8. 8. Maintenance of Health-Related Quality of Life Presented By Paul Ellis at 2015 ASCO Annual Meeting
  9. 9. Overview of Adverse Events Presented By Paul Ellis at 2015 ASCO Annual Meeting
  10. 10. MARIANNE: Toxicities Presented By Shanu Modi at 2015 ASCO Annual Meeting
  11. 11. MARIANNE: CLINICAL IMPACT Presented By Shanu Modi at 2015 ASCO Annual Meeting
  12. 12. Clinical Pathway HER2+ MBC: 2015 Presented By Shanu Modi at 2015 ASCO Annual Meeting
  13. 13. Future for T-DM1 Presented By Shanu Modi at 2015 ASCO Annual Meeting
  14. 14. ATEMPT: Adjuvant HER2+Trial (TBCRC 033) Presented By Shanu Modi at 2015 ASCO Annual Meeting
  15. 15. Slide 19 Presented By Shanu Modi at 2015 ASCO Annual Meeting
  16. 16. L Gianni, T Pienkowski, Y-H Im, L-M Tseng, M-C Liu, A Lluch, <br />E Starosławska, J de la Haba-Rodriguez, S-A Im, JL Pedrini, B Poirier, <br />P Morandi, V Semiglazov, V Srimuninnimit, GV Bianchi, <br />V McNally, H Douthwaite, G Ross, P Valagussa Presented By Luca Gianni at 2015 ASCO Annual Meeting
  17. 17. NeoSphere: study design and objectives Presented By Luca Gianni at 2015 ASCO Annual Meeting
  18. 18. NeoSphere: study design and pCR results Presented By Luca Gianni at 2015 ASCO Annual Meeting
  19. 19. NeoSphere: Phase 2 Neoadjuvant HER2+ Study Presented By Shanu Modi at 2015 ASCO Annual Meeting
  20. 20. Slide 5 Presented By Shanu Modi at 2015 ASCO Annual Meeting
  21. 21. Adjuvant ExteNET Study Design Presented By Shanu Modi at 2015 ASCO Annual Meeting
  22. 22. ExteNET Trial: Invasive DFS, N=2840<br /> Presented By Shanu Modi at 2015 ASCO Annual Meeting
  23. 23. HERA: OS<br />(Duration Question: 2y vs 1y) Presented By Shanu Modi at 2015 ASCO Annual Meeting
  24. 24. ExteNET vs ALTTO and HERA : <br />Why the discrepancy? Presented By Shanu Modi at 2015 ASCO Annual Meeting
  25. 25. Safety (Adverse Events ≥10%) Presented By Shanu Modi at 2015 ASCO Annual Meeting
  26. 26. CONCLUSIONS: HER2+ Breast Cancer Presented By Shanu Modi at 2015 ASCO Annual Meeting
  27. 27. Abstract LBA502 <br /><br /> A Double Blind Phase 3 Trial of Fulvestrant With or Without Palbociclib in Pre- and Post-menopausal Women With Hormone Receptor-positive, HER2- negative Advanced Breast Cancer That Progressed on Prior Endocrine Therapy<br />(PALOMA3 Study) Presented By Nicholas Turner at 2015 ASCO Annual Meeting
  28. 28. Slide 2 Presented By Nicholas Turner at 2015 ASCO Annual Meeting
  29. 29. Palbociclib Presented By Nicholas Turner at 2015 ASCO Annual Meeting
  30. 30. PALOMA3 Study Design Presented By Nicholas Turner at 2015 ASCO Annual Meeting
  31. 31. Study Endpoints Presented By Nicholas Turner at 2015 ASCO Annual Meeting
  32. 32. Adverse Events—All Cause Presented By Nicholas Turner at 2015 ASCO Annual Meeting
  33. 33. Primary Endpoint: PFS (ITT Population) Presented By Nicholas Turner at 2015 ASCO Annual Meeting
  34. 34. Summary of Key Secondary Efficacy Endpoints Presented By Nicholas Turner at 2015 ASCO Annual Meeting
  35. 35. Implications ● First line: Paloma-1 Letrozole +/-palpbociclib ● Second line: Bolero-2 Exemestane +/- everolimus or fulvestrant +/- everolimus ● None showed survival benefit ● Increased toxicity
  36. 36. TITAN: Phase 3 Study of Doxorubicin/Cyclophosphamide (AC) followed by Ixabepilone (Ixa) or Paclitaxel (Pac) in Early-Stage Triple Negative Breast Cancer Presented By Denise Yardley at 2015 ASCO Annual Meeting
  37. 37. Study Design Presented By Denise Yardley at 2015 ASCO Annual Meeting
  38. 38. Key Eligibility Criteria<br /> Presented By Denise Yardley at 2015 ASCO Annual Meeting
  39. 39. Hematologic Toxicity Presented By Denise Yardley at 2015 ASCO Annual Meeting
  40. 40. Non-Hematologic Toxicity (≥ 10%) Presented By Denise Yardley at 2015 ASCO Annual Meeting
  41. 41. Disease-Free Survival (N=614) Presented By Denise Yardley at 2015 ASCO Annual Meeting
  42. 42. Overall Survival (N=614) Presented By Denise Yardley at 2015 ASCO Annual Meeting
  43. 43. Conclusions Presented By Denise Yardley at 2015 ASCO Annual Meeting
  44. 44. Primary Results of NRG Oncology/NSABP B-35: <br />A Clinical Trial of Anastrozole vs Tamoxifen in <br />Postmenopausal Patients with DCIS Presented By Richard Margolese at 2015 ASCO Annual Meeting
  45. 45. Slide 5 Presented By Richard Margolese at 2015 ASCO Annual Meeting N=3,104
  46. 46. Slide 7 Presented By Richard Margolese at 2015 ASCO Annual Meeting
  47. 47. Slide 8 Presented By Richard Margolese at 2015 ASCO Annual Meeting
  48. 48. Slide 12 Presented By Richard Margolese at 2015 ASCO Annual Meeting
  49. 49. B-35: Other Secondary Endpoints Presented By Richard Margolese at 2015 ASCO Annual Meeting
  50. 50. Slide 14 Presented By Richard Margolese at 2015 ASCO Annual Meeting
  51. 51. Slide 17 Presented By Richard Margolese at 2015 ASCO Annual Meeting
  52. 52. B-35: Average Annual Rate and <br />Number of Uterine Cancers Presented By Richard Margolese at 2015 ASCO Annual Meeting
  53. 53. B-35: Thromboembolic Events Presented By Richard Margolese at 2015 ASCO Annual Meeting
  54. 54. B-35: Average Annual Rate and <br />Number of Osteoporotic Fractures Presented By Richard Margolese at 2015 ASCO Annual Meeting
  55. 55. Discussion ● NSABP-B24: Tam vs placebo: Tam better, but side effects ● B-35: AI better for ↓contralateral invasive breast cancer (CinvBC) ● DFS, OS: Same ● An option in DCIS for CinvBC prevention
  56. 56. Thank you! barun@mdanderson.org
  57. 57. Slide 1 Presented By Michael Gnant at 2015 ASCO Annual Meeting
  58. 58. Slide 5 Presented By Michael Gnant at 2015 ASCO Annual Meeting
  59. 59. Slide 6 Presented By Michael Gnant at 2015 ASCO Annual Meeting
  60. 60. Slide 15 Presented By Michael Gnant at 2015 ASCO Annual Meeting
  61. 61. Slide 16 Presented By Michael Gnant at 2015 ASCO Annual Meeting
  62. 62. Slide 19 Presented By Michael Gnant at 2015 ASCO Annual Meeting
  63. 63. Slide 20 Presented By Michael Gnant at 2015 ASCO Annual Meeting
  64. 64. Slide 22 Presented By Michael Gnant at 2015 ASCO Annual Meeting
  65. 65. Thank you! barun@mdanderson.org

×